Science Corporation is valued at $3.5 billion after raising $400 million for its PRIMA retinal implant

Startups & Funding

Science Corporation Hits $3.5 Billion Valuation on $400 Million Series D

Science Corporation raised a $400 million Series D at a $3.5 billion valuation to expand PRIMA, its CE-marked retinal implant for late-stage macular degeneration, now on sale in Germany.

By
Grace Kim
Filed
Channel
Startups & Funding
Read
2 min read

Science Corporation is now valued at $3.5 billion after raising a $400 million Series D to scale its PRIMA retinal implant. The round, announced Tuesday, Nov. 17, lifts total capital raised by the brain-computer interface company to more than $900 million since its founding in 2021.

The valuation is more than double the $1.5 billion Science reached in March, when it closed a $230 million Series C, as Bloomberg reported at the time. A person familiar with the new deal confirmed the $3.5 billion figure to TechCrunch.

The Series D backers include:

  • Khosla Ventures
  • The Ackman Oxman Institute
  • Tenet Healthcare
  • 885 Capital
  • Y Combinator
  • PLC Neurotech

Science was founded in 2021 by Max Hodak, a former president of Neuralink. The company has now raised more than $900 million across its lifetime.

What is PRIMA and where is it sold?

PRIMA is Science's first product. It is a wearable and implantable chip system that restores form vision, the ability to read letters, numbers and words, for some patients blinded by late-stage age-related macular degeneration. The company says it is the first brain-computer interface to receive a CE mark for that use.

The system is on sale in Germany. In October, Science reported 36-month results from the PRIMA trial showing durable vision restoration in patients with geographic atrophy, an advanced form of macular degeneration.

Science said the new capital will speed PRIMA's availability across Europe and prepare a US launch.

How does Science plan to enter the US market?

The company is pursuing FDA approval through the Humanitarian Device Exemption, a pathway reserved for devices that treat rare conditions. TechCrunch reported that Science has persuaded the FDA that advanced macular degeneration in both eyes is uncommon enough to qualify for that pathway.

Hodak said on stage at TechCrunch Disrupt that PRIMA is now being trialled in patients with Stargardt disease, an inherited cause of blindness. That expands the potential patient population beyond age-related macular degeneration.

Where else will the money go?

Beyond commercialization, the Series D funds research, manufacturing and Science's biohybrid program. The program is a neural interface that grows engineered neurons on silicon to connect with the brain's own circuits.

Science is designing the first human trials of the biohybrid device with Murat Günel, a neurosurgery professor at Yale. Günel told TechCrunch the device could offer treatments for Parkinson's disease and other brain injuries and illnesses.

The round lands days after rival Synchron paused trials of its wireless Stentrode implant over a faulty lead, sharpening the competitive stakes in the implantable neural device field. With CE-marked revenue in Germany, a US regulatory pathway in motion and $400 million in fresh capital, Science now holds the most advanced commercial position among brain-computer interface startups chasing the ophthalmology market.

Source: mlq.ai

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering people, launches and day-to-day practice in Semiconductors, chip manufacturing, hardware, AI compute at Chip Dispatch.

1,062 articles

Related articles

« Previous articleNext article »